GSK buys rights to TIGIT-targeted cancer immunotherapy from Iteos

Iteos Therapeutics said Monday that it has sold ownership rights to an experimental anti-TIGIT cancer antibody to GlaxoSmithKline — the most recent and largest licensing deal yet for a drug in the unproven, but highly sought-after class of immunotherapy treatments.

Glaxo has struggled to compete against its pharma rivals in the cancer drug business, so it had little choice but to pay up big for rights to an anti-TIGIT drug — in this case, an upfront cash payment of $625 million for rights to the drug, called EOS-448.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Source link


The leading source for trustworthy and timely health and medical news and information. Providing credible health information, supportive community, and educational services by blending award-winning expertise in content, community services, expert commentary, and medical review. Everything about health is here with the difference of Dr.About

Related Articles

Leave a Reply

Back to top button